The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 26, 2023

Filed:

Apr. 13, 2018
Applicants:

Cellectis, Paris, FR;

Albert-ludwigs-universitat Freiburg, Freiburg, DE;

Inventors:

Toni Cathomen, Freiburg, DE;

Tatjana Cornu, Freiburg, DE;

Philippe Duchateau, Draveil, FR;

Claudio Mussolino, Freiburg, DE;

Marianna Romito, Freiburg, DE;

Agnes Gouble, Bois-Colombes, FR;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); C12N 5/0789 (2010.01); A61P 31/18 (2006.01); A61K 35/17 (2015.01); C07K 14/715 (2006.01); C12N 15/90 (2006.01); C12N 15/85 (2006.01); C12N 15/67 (2006.01); C12N 5/0783 (2010.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C12N 5/0647 (2013.01); A61K 35/17 (2013.01); A61P 31/18 (2018.01); C07K 14/7158 (2013.01); C12N 5/0636 (2013.01); C12N 9/22 (2013.01); C12N 15/67 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A61K 38/00 (2013.01);
Abstract

The invention pertains to the field of cell therapy and HIV treatments. It provides with highly specific reagents for reducing or inactivating expression of CCR5 in primate and human primary cells, especially under the form of TALE-nucleases. These reagents allow the production of safer primary hematopoietic cells made resistant to HIV, stem cells or differentiated cells, for their infusion into HIV patients.


Find Patent Forward Citations

Loading…